OnePin Peptide Library · Pain Relief
Dermorphin
Dermorphin Acetate · DRM
Dermorphin is a heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser) originally isolated from the skin of South American Phyllomedusa frogs. It is a highly selective mu-opioid receptor agonist with 30-40 times the analgesic potency of morphine on a per-molecule basis. Notably contains a D-alanine residue at position 2 - the first naturally-occurring D-amino-acid-containing peptide identified - which confers metabolic stability against enzymatic degradation.
Strongly discouraged for non-research use. Naloxone availability mandatory for any opioid handling. Cross-tolerance with all other opioids.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Dermorphin binds mu-opioid receptors (μ-OR / OPRM1) with high selectivity and 30-40x greater potency than morphine on a per-molecule basis. Mu-OR activation triggers Gi/Go signaling, inhibiting adenylyl cyclase, reducing cAMP, and activating G-protein-coupled inwardly rectifying potassium (GIRK) channels - net producing neuronal hyperpolarization and decreased neurotransmitter release.
Analgesia
Spinal and supraspinal mu-OR activation produces potent analgesia, particularly for visceral and somatic pain.
D-Alanine Stability
The D-amino acid at position 2 resists enzymatic degradation - dermorphin survives proteolysis better than mammalian opioid peptides like enkephalins, giving it a longer functional duration.
Reward / Reinforcement
Mu-OR activation in the ventral tegmental area and nucleus accumbens drives the reward circuitry - basis of euphoria and addictive potential. Standard opioid abuse pharmacology applies.
Respiratory Depression
Mu-OR in the brainstem respiratory centers - dose-dependent respiratory depression is the dominant overdose risk. Naloxone reverses dermorphin overdose effectively (mu-OR is competitive antagonism target).
Cross-Tolerance
Cross-tolerant with other mu-opioid agonists (morphine, fentanyl, oxycodone, heroin). Withdrawal symptoms similar to other opioids.
Potency Caveat
30-40x morphine potency means small volume errors translate to large dose errors - high overdose risk in research-chemical handling.
What to expect
Acute analgesic and euphoric effect within 30-60 min of SubQ dosing.
Tolerance develops with repeated use; dose escalation typical.
Dependence syndrome; withdrawal upon cessation.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Side effects & safety
Commonly reported
- Sedation
- Respiratory depression
- Constipation
- Nausea
- Pruritus (opioid-class itch)
- Euphoria
Less common & notes
- Severe respiratory depression and overdose death - the dominant opioid mortality pathway.
- Tolerance, dependence, and withdrawal syndrome.
- Hyperalgesia with chronic use.
- Hypotension.
- Pulmonary edema (rare).
- Allergic reactions rare.
- The high potency vs morphine combined with research-chemical-grade variability in actual peptide content makes overdose risk substantial.
Pharmacokinetics
Storage. Refrigerate. Lyophilized form more stable.
Regulatory status
Not FDA-approved for any human indication. Functionally a high-potency opioid - while sold as research chemical, regulatory enforcement against opioid distribution may apply depending on jurisdiction. WADA prohibited under class S6 (narcotics) and various racing authority bans. Strongly discouraged for non-research use.
Put it to work
Calculate, log & track
Open Dermorphin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Dermorphin in the app →Go deeper
The guide & community
The complete Dermorphin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗